Eysz, Inc.

Eysz, Inc.Eysz, Inc.Eysz, Inc.

Eysz, Inc.

Eysz, Inc.Eysz, Inc.Eysz, Inc.
  • Home
  • Blog
  • More
    • Home
    • Blog
  • Home
  • Blog

Transforming Neurological Care

Transforming Neurological CareTransforming Neurological CareTransforming Neurological Care

Neurological Disorders by the Numbers

1 Billion

$1.6 Trillion

6.8 Million

People with Neurological 

Disorders Globally

6.8 Million

$1.6 Trillion

6.8 Million

Deaths from Neurological 

Disorders each Year

$1.6 Trillion

$1.6 Trillion

$1.6 Trillion

Combined Economic Burden in Europe and the USA alone 

The PROBLEM

Lack of Biomarkers

Most brain disorders lack a biomarker (i.e, a way to measure disease progression).  As a result, clinicians rely on subjective scales to measure efficacy of treatment which typically result in increased costs, poor patient outcomes, and years of time spent trying to find the right treatment.   

Increased Costs while outcomes stagnant

A recent study showed that in the USA, direct costs related to Epilepsy have almost doubled in the last decade to $28B per year, while outcomes have not improved in almost three decades.

The Parents' Perspective

For Patients, it is even more difficult to be the 'eyes' of the clinicians outside of the clinic, particularly in trying to keep track of disease progression given the lack of knowledge of what to look for and if they are doing it well.  Hear the perspective of Amy and David - parents of a child diagnosed with epilepsy. 

The solution

Eysz is building a passive neurological exam using real world data.  By leveraging oculometric data from consumer grade eye-tracking systems, our software algorithms have the potential to reliably detect consciousness and other neurological 'vital signs' such as cognition and mood.  While our initial focus will be Epilepsy, our aim is to expand to other neurological disorders.   

The Potential Benefits

Improving Outcomes

Improving Quality of Life

Improving Quality of Life

By helping clinicians get the data they need to identify the right treatments sooner. 

Improving Quality of Life

Improving Quality of Life

Improving Quality of Life

Relieving patients and caregivers from the burden of self-reporting.

Reducing Costs

Improving Quality of Life

Reducing Costs

Reduce the number of costly visits to the hospital.

The Evidence

Preliminary

We completed a 30 patient proof-of-concept study which resulted in robust seizure detection of the subtlest seizure type, absence seizures.

Recent

We have completed an in-depth clinical study involving 4 clinical collaborators that have been designated Level 4 by the National Association of Epilepsy Centers to help us collect the oculometric data needed to identify the initial accuracy of our software.

Our Team

Rachel Kuperman, MD, Founder & CEO

Parth Amin, Co-Founder and COO

Parth Amin, Co-Founder and COO

Neurologist with dual certification in epilepsy and neurology with over 10 years’ experience directing the clinical epilepsy and research programs at UCSF Benioff Children’s Hospital, Oakland

Parth Amin, Co-Founder and COO

Parth Amin, Co-Founder and COO

Parth Amin, Co-Founder and COO

Leads our Product Development efforts and GTM Strategy.  Brings 15+ Years Medical Device Experience in Product and Project Management, Product Launch, and Alliances having worked at Siemens Healthineers, Varian, and Omnicell. 

Jit Sarkar, PhD, Co-Founder and CTO

Parth Amin, Co-Founder and COO

Jit Sarkar, PhD, Co-Founder and CTO

Leads the algorithm development for Eysz solution. He completed his undergraduate degree in computer science and has deep experience applying machine learning methods. His PhD from UCSD focused on extracting signals from a complex medium.

Julia Martinez Franks, Product Manager

Nate Blanco, Phd Data Scientist

Jit Sarkar, PhD, Co-Founder and CTO

Responsible for advancing our solution from clinical trials, development, to obtaining regulatory clearnaces.  She completed the UC Berkeley and UC San Francisco’s Masters in Translational Medicine (MTM) program given her passion bringing innovation in healthcare to market.

Nate Blanco, Phd Data Scientist

Nate Blanco, Phd Data Scientist

Nate Blanco, Phd Data Scientist

Brings experience in research, statistical analysis, and computational modeling in the field of cognitive neurosicience —most recently as a postdoctoral researcher in the Cognitive Development Lab at the Ohio State University.  He completed his PhD from University of Texas in Cogntitive Neuroscience.

Our Advisors

Robert Fisher, MD, PhD Scientific Advisor

Robert Fisher, MD, PhD Scientific Advisor

Robert Fisher, MD, PhD Scientific Advisor

Dr. Fisher is Maslah Saul MD Professor and Director of the Stanford  Epilepsy Center. He had research awards from the Klingenstein  Foundation, EF, CURE and NIH. He published 160 peer-reviewed articles  and 4 books. He was named 1996-2016 in Best Doctors in America.  Dr. Fisher is Past-President of the American Epilepsy  Society, and has 

Dr. Fisher is Maslah Saul MD Professor and Director of the Stanford  Epilepsy Center. He had research awards from the Klingenstein  Foundation, EF, CURE and NIH. He published 160 peer-reviewed articles  and 4 books. He was named 1996-2016 in Best Doctors in America.  Dr. Fisher is Past-President of the American Epilepsy  Society, and has served on the Board of the ILAE and as Editor-in-Chief  of the Journal, Epilepsia.  His research is on new devices to treat epilepsy.   

Hal Blumenfeld, MD, PhD Scientific Advisor

Robert Fisher, MD, PhD Scientific Advisor

Robert Fisher, MD, PhD Scientific Advisor

Dr. Blumenfeld's clinical and research work focuses on epilepsy, cognition and brain  imaging. He directs Yale's Clinical Neuroscience Imaging Center (CNIC), a  new multi-disciplinary core facility for innovative study and treatment  of brain disorders. Teaching activities include a textbook titled  Neuroanatomy Through Clinical Cases, Sinauer Assoc., Publ. 2002, 2010. 

Nicolle Napier-Ionascu, PsyD Scientific Advisor

Nicolle Napier-Ionascu, PsyD Scientific Advisor

Nicolle Napier-Ionascu, PsyD Scientific Advisor

Practicing neuropsychology for over 12 years. She is also the head Neuropsychologist in the Epilepsy department at UCSF Benioff Children’s Hospital Oakland.  

Peter Milford, PhD Technical Advisor

Nicolle Napier-Ionascu, PsyD Scientific Advisor

Nicolle Napier-Ionascu, PsyD Scientific Advisor

Dr. Milford has over 15 years experience in developing high technology instrumentation. He was CTO of Eyefluence, which was developing the next generation eye-tracking wearable technology,  up until October 2016, when purchased by Google. He  continued to develop eye interaction and eye tracking for augmented reality (AR) and virtual real

Dr. Milford has over 15 years experience in developing high technology instrumentation. He was CTO of Eyefluence, which was developing the next generation eye-tracking wearable technology,  up until October 2016, when purchased by Google. He  continued to develop eye interaction and eye tracking for augmented reality (AR) and virtual reality (VR) headsets.  He now serves as the President of Parallel Rules consulting firm.  

Board

Randy Berholtz JD, MBA

Randy Berholtz JD, MBA

Randy Berholtz JD, MBA

Randy leverages his corporate experience, where he has held roles as a corporate and business development executive and as general counsel, to help nurture over 25 startups in healthcare from funding, to serving as a board of director to corporate and business development and strategic initiatives.  He currently serves as a Partner for Ve

Randy leverages his corporate experience, where he has held roles as a corporate and business development executive and as general counsel, to help nurture over 25 startups in healthcare from funding, to serving as a board of director to corporate and business development and strategic initiatives.  He currently serves as a Partner for Ventac Partners and a Senior Advisor for Mesa Partners.  He is also a parent of a child with epilepsy.

Colin Lake

Randy Berholtz JD, MBA

Randy Berholtz JD, MBA

Colin is the Head of Digital Transformation Neurology at UCB Pharma, the global leaders in the field of epilepsy research and medicine development. Colin brings decades of global executive experience in pharma and digital health innovation. In his current role, Colin spearheads UCB’s efforts to improve the support for patients and key sta

Colin is the Head of Digital Transformation Neurology at UCB Pharma, the global leaders in the field of epilepsy research and medicine development. Colin brings decades of global executive experience in pharma and digital health innovation. In his current role, Colin spearheads UCB’s efforts to improve the support for patients and key stakeholders in the healthcare ecosystem by driving UCB’s ambitious digital agenda. While currently living in the U.S., Colin is originally from the U.K. and has been fortunate enough to live and work in seven different countries.

Drop us a line with any questions, comments, or inquiries you may have or if you want to simply stay in touch.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.



Copyright © 2020 Eysz, Inc. - All Rights Reserved.

Powered by GoDaddy